The cost of ticagrelor varies based on factors such as dosage, quantity, and insurance coverage. Without insurance, a 30-day supply of ticagrelor 90 mg can range from approximately $300 to over $500 [1]. Prices can differ significantly between pharmacies.
How can I find cheaper ticagrelor?
Patients may find lower prices for ticagrelor through several avenues. Using discount cards or coupons from pharmaceutical manufacturers or third-party discount providers can reduce out-of-pocket expenses [1]. Comparing prices across different pharmacies, including online and local options, is also recommended. For individuals with prescription drug coverage, the cost is typically determined by their insurance plan's formulary and co-payment structure.
What is the generic name for ticagrelor?
Ticagrelor is the generic name for the medication. It is marketed under the brand name Brilinta [2].
When will generic versions of ticagrelor be available?
The availability of generic versions of ticagrelor is subject to patent protections. Information regarding patent expiry dates and the potential for generic entry can be found on resources like DrugPatentWatch.com [3]. As of recent data, some generic versions have become available [4].
How does ticagrelor work in the body?
Ticagrelor is an antiplatelet medication that works by preventing platelets in the blood from clumping together. This action reduces the risk of blood clot formation, which can lead to heart attack or stroke [2].
What are the common dosages for ticagrelor?
Ticagrelor is commonly prescribed in dosages of 90 mg twice daily for patients with acute coronary syndrome. In some cases, after a period of treatment with 90 mg, a lower maintenance dose of 60 mg twice daily may be prescribed [2].
What are the potential side effects of ticagrelor?
Common side effects associated with ticagrelor include bleeding, shortness of breath, and slow heart rate [2]. Patients experiencing any adverse effects should consult their healthcare provider.
Who manufactures ticagrelor?
Ticagrelor, under the brand name Brilinta, is manufactured by AstraZeneca [2].
How does ticagrelor compare to other antiplatelet drugs?
Ticagrelor is a P2Y12 inhibitor, similar to clopidogrel (Plavix) and prasugrel (Effient). While all work to prevent platelet aggregation, they differ in their mechanism of action, potency, onset of action, and side effect profiles. Ticagrelor is a reversible inhibitor, meaning its effect on platelets can be reversed more quickly than some other P2Y12 inhibitors [2].
What clinical studies support the use of ticagrelor?
The efficacy and safety of ticagrelor have been demonstrated in several large clinical trials, including the PLATO (A Study of Ticagrelor in Patients with Acute Coronary Syndromes) trial, which compared ticagrelor to clopidogrel in patients with ACS [2].
What are the risks associated with taking ticagrelor?
The primary risk associated with ticagrelor is bleeding, which can range from minor to life-threatening. Other risks include shortness of breath and bradycardia (slow heart rate). Patients with a history of bleeding disorders or those taking other medications that increase bleeding risk may be at higher risk [2].
Sources:
[1] GoodRx. (n.d.). Ticagrelor Prices, Coupons, and Patient Assistance Programs. Retrieved from https://www.goodrx.com/ticagrelor
[2] National Library of Medicine. (n.d.). Ticagrelor. Retrieved from https://medlineplus.gov/druginfo/meds/a610009.html
[3] DrugPatentWatch.com. (n.d.). Ticagrelor Patents. Retrieved from https://www.drugpatentwatch.com/ticagrelor
[4] U.S. Food & Drug Administration. (n.d.). ANDA Status. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=processforapproval.details&Appl_No=207121